循环RNAs在血液恶性瘤中的近期进展
Ya-Bin Cui1, Li-Jie Wang1, Jin-Hui Xu2
1Department of Hematology, Henan University People's Hospital and Henan Provincial People's Hospital, Zhengzhou 450003, P.R. China.
International journal of medical sciences
|October 23, 2024
概括
循环RNAs (circRNAs) 是血液癌症中至关重要的表观遗传调节剂. 这次审查强调了它们在疾病进展中的作用和作为生物标志物和治疗点的潜力.
科学领域:
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 在瘤学瘤学.
背景情况:
- 循环RNAs (circRNAs) 是关键的表观遗传调节者,参与细胞活动,如增殖和亡.
- 它们的稳定结构使得它们成为疾病诊断和预后的有希望的生物标志物,特别是在血液性恶性瘤中.
研究的目的:
- 审查circRNAs在血液性恶性瘤的发病,进展和治疗抵抗中的作用.
- 探索circRNAs在预测疾病结果和治疗反应中的预后意义.
主要方法:
- 关于血液恶性瘤中circRNAs研究的综合文献综述.
- 对circRNA参与癌症生物学,诊断,预后和治疗的分析.
主要成果:
- 循环RNA在血液癌症的发展和进展中起着重要作用.
- 循环RNAs显示出作为患者结果和治疗疗效的预测生物标志物的潜力.
- 循环RNAs与血液性恶性瘤的治疗抵抗有关.
结论:
- 循环RNA在血液恶性瘤中起着关键作用,影响病变发生和治疗反应.
- 循环RNA为血液癌症的新型诊断和治疗策略提供了一个有希望的途径.
相关概念视频
Hematopoiesis
5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K


